HUE059947T2 - Eljárás tetrahidrokinolin-származékok elõállításához való szintézis-köztitermékek elõállítására - Google Patents

Eljárás tetrahidrokinolin-származékok elõállításához való szintézis-köztitermékek elõállítására

Info

Publication number
HUE059947T2
HUE059947T2 HUE15767345A HUE15767345A HUE059947T2 HU E059947 T2 HUE059947 T2 HU E059947T2 HU E15767345 A HUE15767345 A HU E15767345A HU E15767345 A HUE15767345 A HU E15767345A HU E059947 T2 HUE059947 T2 HU E059947T2
Authority
HU
Hungary
Prior art keywords
preparing
synthetic intermediates
tetrahydroquinoline derivatives
derivatives
preparing synthetic
Prior art date
Application number
HUE15767345A
Other languages
English (en)
Hungarian (hu)
Inventor
John Ford
Johannes Paulus Gerardus Seerden
Amandine Ledru
Original Assignee
Newamsterdam Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE059947(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newamsterdam Pharma B V filed Critical Newamsterdam Pharma B V
Publication of HUE059947T2 publication Critical patent/HUE059947T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUE15767345A 2014-08-12 2015-07-29 Eljárás tetrahidrokinolin-származékok elõállításához való szintézis-köztitermékek elõállítására HUE059947T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12

Publications (1)

Publication Number Publication Date
HUE059947T2 true HUE059947T2 (hu) 2023-01-28

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15767345A HUE059947T2 (hu) 2014-08-12 2015-07-29 Eljárás tetrahidrokinolin-származékok elõállításához való szintézis-köztitermékek elõállítására

Country Status (28)

Country Link
US (1) US10112904B2 (enExample)
EP (2) EP4083022A1 (enExample)
JP (1) JP6670310B2 (enExample)
KR (1) KR102572626B1 (enExample)
CN (1) CN107108558B (enExample)
AR (1) AR101509A1 (enExample)
AU (1) AU2015302407B2 (enExample)
BR (1) BR112017002873B1 (enExample)
CA (1) CA2958040C (enExample)
CL (1) CL2017000367A1 (enExample)
CY (1) CY1125574T1 (enExample)
DK (1) DK3180314T3 (enExample)
EA (1) EA034357B1 (enExample)
ES (1) ES2926775T3 (enExample)
HR (1) HRP20221061T1 (enExample)
HU (1) HUE059947T2 (enExample)
IL (1) IL250525B (enExample)
LT (1) LT3180314T (enExample)
MA (1) MA40378B1 (enExample)
MX (1) MX367908B (enExample)
PL (1) PL3180314T3 (enExample)
PT (1) PT3180314T (enExample)
RS (1) RS63575B1 (enExample)
SG (1) SG11201701077XA (enExample)
SI (1) SI3180314T1 (enExample)
SM (1) SMT202200385T1 (enExample)
TW (1) TWI691490B (enExample)
WO (1) WO2016024858A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2988112T3 (es) 2021-03-05 2024-11-19 Newamsterdam Pharma B V Obicetrapib para el tratamiento de demencias
IL310115A (en) 2021-07-26 2024-03-01 Newamsterdam Pharma B V Treatment of his hyporesponders
CA3242880A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
WO2024042061A1 (en) 2022-08-22 2024-02-29 Newamsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
EP4746866A1 (en) 2024-09-17 2026-05-27 NewAmsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026062049A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias
WO2026063944A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias
WO2026087915A1 (en) 2024-10-25 2026-04-30 Newamsterdam Pharma B.V. Treatment and prevention of sepsis or other dysregulated inflammatory responses using cetp inhibitor obicetrapib
WO2026115019A1 (en) 2024-11-27 2026-06-04 Newamsterdam Pharma B.V. Enantioselective process for preparing tetrahydroquinoline derivatives
WO2026146129A1 (en) 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Magnesium salts of obicetrapib
WO2026146132A1 (en) 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Salts of obicetrapib
WO2026146133A1 (en) 2025-01-02 2026-07-09 Newamsterdam Pharma B.V. Deuterated derivatives of obicetrapib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法

Also Published As

Publication number Publication date
ES2926775T3 (es) 2022-10-28
TWI691490B (zh) 2020-04-21
PT3180314T (pt) 2022-09-02
MX2017001930A (es) 2018-03-01
AU2015302407B2 (en) 2019-09-19
US10112904B2 (en) 2018-10-30
MX367908B (es) 2019-09-11
EA201790364A1 (ru) 2017-07-31
KR102572626B1 (ko) 2023-08-30
PL3180314T3 (pl) 2022-11-21
MA40378A (fr) 2017-06-21
BR112017002873A2 (pt) 2018-07-17
CY1125574T1 (el) 2026-02-25
CN107108558B (zh) 2019-11-19
EP3180314B1 (en) 2022-06-22
CL2017000367A1 (es) 2018-02-09
IL250525A0 (en) 2017-03-30
AR101509A1 (es) 2016-12-21
JP6670310B2 (ja) 2020-03-18
CA2958040A1 (en) 2016-02-18
BR112017002873B1 (pt) 2023-03-28
SI3180314T1 (sl) 2022-11-30
TW201613868A (en) 2016-04-16
WO2016024858A1 (en) 2016-02-18
IL250525B (en) 2019-08-29
MA40378B1 (fr) 2022-10-31
KR20170102204A (ko) 2017-09-08
SG11201701077XA (en) 2017-03-30
US20170267640A1 (en) 2017-09-21
HRP20221061T1 (hr) 2022-11-25
CA2958040C (en) 2022-09-13
EP4083022A1 (en) 2022-11-02
LT3180314T (lt) 2022-11-10
EP3180314A1 (en) 2017-06-21
CN107108558A (zh) 2017-08-29
EA034357B1 (ru) 2020-01-30
DK3180314T3 (da) 2022-08-29
BR112017002873A8 (pt) 2022-11-08
AU2015302407A1 (en) 2017-03-02
JP2017524742A (ja) 2017-08-31
RS63575B1 (sr) 2022-10-31
SMT202200385T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
SG11201701077XA (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
ZA201708142B (en) Process for preparing 4-amino-pyridazines
IL252912A0 (en) Processes for preparing oxathiazine-like compounds
PL3196196T3 (pl) Sposób wytwarzania kalcobutrolu
PT3160932T (pt) Processo para a produção de nitrobenzeno
IL248267B (en) A process for preparing converted cycloserines
PL3295941T3 (pl) Sposób wytwarzania postaci a grapiprantu
SG11201606862VA (en) Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
IL253877B (en) Process for the preparation of 3-chloro-2-vinylphenylsulfonates
GB201405359D0 (en) Synthetic process
IL248565A0 (en) A process for the preparation of thiazole derivatives
IL243795A0 (en) A process for the preparation of a quinazoline derivative
SG11201701118TA (en) Improved process for alaknolamide synthesis
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives
IL249283B (en) Process for the preparation of 3-chloro-2-vinylphenol
HUE064118T2 (hu) Harmonika csatlakozószerkezethez
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni
ZA201701100B (en) Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
IL241974A0 (en) Process for making erlotinib
IL253630B (en) A process for the preparation of modified phenylisoxazoline derivatives
EP3233732B8 (en) Process for preparing monohydrogentrihalosilanes